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Introduction
Th  ere is considerable variability in progression rates 
among Alzheimer’s disease (AD) patients. Patients and 
families frequently ask clinicians to prognosticate regard-
ing expected rates of cognitive and functional decline, 
and clinicians have little basis for making such 
predictions. We have shown that it is possible to reliably 
estimate early AD symptom onset, and together with 
baseline MMSE score, to calculate a rate of progression at 
the initial assessment (the pre-progression rate) [1, 2]. 
Th  e use of a rate to estimate early progression gives 
information on severity, but also on how long it took for 
the patient to reach the current severity level, which 
reﬂ  ects that individual’s disease characteristics better than 
a severity score alone. However, it is not clear whether 
patients maintain a similar rate of decline throughout the 
course of their disease or change trajectories over time, 
due to endogenous or exogenous factors (such as 
treatment). Demonstrating the predictive value of the 
calculated pre-progression rate would be valuable for 
patient and family counseling, as well as for providing a 
research marker of phenotypic variability to validate 
biological markers of progression. Further, the ability to 
model group progression of AD patients is essential for 
designing disease-modiﬁ   cation studies of new AD 
treatments, and pre-progression might be an important 
baseline variable to take into account in the analysis of 
clinical trial data [3].
Th   e Baylor Alzheimer’s Disease and Memory Disorders 
Center has followed a cohort of AD patients for up to 15 
years, with detailed clinical and neuropsychological data 
obtained at baseline and at annual follow up visits which 
are maintained in an ongoing electronic data base. We 
used these data to answer the following questions: 1) 
does a pre-progression rate calculated at the initial 
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medium, provided the original work is properly cited.assessment predict subsequent performance in speciﬁ  c 
cognitive and functional domains during follow up, and 
2) is the pre-progression rate associated with overall 
survival, after adjustment for relevant covariates?
Materials and methods
Th  e Baylor Alzheimer’s Disease and Memory Disorders 
Center sees self-referred, agency-referred, and physician-
referred individuals for evaluation and management of 
cognitive complaints. We evaluate patients for systemic 
and brain disorders with laboratory testing, including 
neuroimaging, and psychometric tests. We assign a 
diagnosis of various subtypes of mild cognitive impair-
ment (MCI) or dementia according to standardized 
criteria through a consensus conference [4, 5]. Details of 
the Baylor ADMDC patient recruitment, assessment, 
follow up procedures, and long-term clinical outcomes in 
the patient cohort have been reported [5]. Patients who 
meet standardized diagnostic criteria for probable or 
possible Dementia with Lewy Bodies are excluded from 
the Probable AD diagnostic category. Patients included in 
this analysis are enrolled in the Baylor Alzheimer’s 
Disease Center and the database has been approved by 
the Baylor Institutional Review Board. Patients and/or 
their legally designated representative sign consent for 
storage and use of their data.
Measures
Cognitive outcome measures routinely obtained at 
baseline and at annual follow up include the Mini Mental 
Status Exam (MMSE), [6] a widely used dementia severity 
test with scores ranging from 0 to 30 points, and the 
Alzheimer’s disease Assessment Scale-Cognitive Subscale 
(ADAS), [7] a measure of cognitive domains often 
impaired in AD including memory, orientation, visuo-
spatial ability, language, and praxis. Scores range from 0 
to 70 with higher scores reﬂ  ecting more cognitive impair-
ment. Attention and concentration are assessed with the 
Verbal Series Attention Test (VSAT) [8]. Th   is test consists 
of forward and reverse generation of arithmetic series, 
verbal series (for example, months of the year), number-
letter sequencing and auditory vigilance for a spoken 
target letter and is scored for time taken to complete each 
task (up to 480 seconds) and the number of errors made 
(up to 45). To assess global performance we use the 
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) 
[9, 10]. Th   is score is derived from a patient interview and 
mental status examination in conjunction with an 
interview of a collateral source. Th   e CDR-SB score (range 
0 to 18) is obtained by summing ratings in each of six 
cognitive domains or boxes including memory, orienta-
tion, judgment/problem solving, community aﬀ  airs, 
home and hobbies, and personal care. Higher scores 
reﬂ  ect more global impairment. Functional outcomes are 
assessed with the Physical Self-Maintenance Scale 
(PSMS) and Instrumental Activities of Daily Living scale 
(IADL), which together constitute the Lawton and Brody 
Activities of Daily Living Scale [11]. Th   e PSMS quantiﬁ  es 
diﬃ     culties with basic activities of daily living such as 
eating and dressing, and each item is scored from 1 to 5 
with a maximal score of 30, representing maximal 
impairment. Th  e IADL evaluates eight complex daily 
living tasks such as the use of the telephone, ability to 
shop, and to make use of transportation. Scores range 
from zero to 31, with higher scores indicating more 
functional impairment.
Covariates previously reported to inﬂ  uence progression 
in AD and routinely collected at the baseline visit are pre-
morbid IQ estimated by the American version of the New 
Adult Reading Test (AMNART) [12, 13], age, sex, years of 
education, history or presence of hallucinations, delusions, 
and extra-pyramidal signs [14, 15]. In our previous work, 
premorbid IQ was a better predictor of progression rates 
than education [16], and this was taken into account in the 
modeling described below. We used a modiﬁ  cation of the 
motor scale of the Uniﬁ  ed Parkinson’s disease Rating Scale 
to capture extra-pyramidal signs [17].
Vital status is obtained from the National Death Index 
every six months, with a censoring date on December 31, 
2004.
Calculation of pre-progression rate
Th   e pre-progression rate is calculated using a clinician’s 
standardized assessment of symptom duration in years 
and the baseline MMSE. We obtain the clinician estimate 
of duration using a standard procedure which includes a 
series of questions about the duration of speciﬁ  c 
symptoms that might be a sign of AD, combined with 
medical records review, an informant interview, and 
hypothesis-testing. Inter-rater reliability for the estimate 
is 0.95 [2]. Since a cognitively intact individual should 
obtain the maximum MMSE score of 30, the pre-
progression rate is given by the formula: (30 – baseline 
MMSE)/estimated duration of symptoms in years. 
Patients with an MMSE decline of less than two points 
per year are classiﬁ   ed as slow progressors, between a 
two- to four-point decline as intermediate progressors, 
and more than or equal to ﬁ  ve points per year as rapid 
progressors [1]. In a previous study, we found that use of 
a normed MMSE score, based upon age, education, and 
gender [18] underestimated the baseline MMSE score for 
7% of the subjects [1], which is why we have adopted the 
maximal score of 30 in our formula. Since MMSE decline 
is non-linear, we used groupings of MMSE change rates 
(slow, intermediate, rapid) which are more clinically 
relevant than absolute rates of change (for example, one 
point per year is really not clinically diﬀ  erent from two 
points per year because of test-retest variability).
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Only probable AD patients (NINCDS-ADRDA, DSM IV) 
were included. Patients had to have a pre-progression 
index calculated at baseline, an AMNART score, and at 
least one comprehensive follow-up visit approximately 
one year later.
Th  e  ﬁ  rst patient was enrolled in 1989, and accrual has 
been ongoing since then. Th  e AMNART was incor-
porated in 1994. Th   e ADAS-Cog, PSMS, and IADL scales 
were not used routinely until 1995, whereas other 
outcome measures were collected in earlier years. Rather 
than requiring all patients to have all of the outcome 
measures, we allowed individuals to enter each analysis if 
they had a measure of the outcome in question and non-
missing values on the adjustment covariates. We report 
in the Results section the number of persons included in 
each regression equation.
Statistical analysis
Th  e study data are longitudinal, with ﬁ  xed  values 
associated with demographic characteristics and baseline 
clinical presentation, and time varying values on cogni-
tive and functional outcomes. For the analysis of progres-
sion of AD, we used random eﬀ  ects linear regression 
models to estimate the relationship between the pre-
progression categories and the rate of change in the 
ADAS-Cog, VSAT Time, VSAT Errors, CDR Sum of 
Boxes, PSMS and IADL scores [19]. Coeﬃ   cients yielded 
by this type of model reﬂ  ect the change, or slope, in the 
outcome for each unit change in a predictor variable, 
holding values of the other variables in the model 
constant. Th   e random eﬀ  ect is time in years, and we used 
a time by pre-progression rate interaction term to 
indicate whether or not there is a diﬀ  erence in average 
rate of decline (slope) associated with a patient’s initially 
calculated pre-progression group. A signiﬁ  cant time by 
pre-progression rate interaction term could represent 
divergence among the groups in rates of change. We 
examined each model for signiﬁ  cance of a quadratic term 
and used non-linear interactions when the quadratic was 
signiﬁ   cant (but report both the linear and non-linear 
interactions in Table 1). Potential confounders or eﬀ  ect 
modiﬁ  ers of the association between cognitive or func-
tional outcomes and the pre-progression rate included 
age, sex, race/ethnicity (non-Hispanic whites vs. Hispanic 
whites, blacks and other ethnicities), years of education, 
AMNART score (as a measure of pre-morbid IQ), and 
baseline clinical features of history or presence of halluci-
nations, delusions, and Parkinsonian signs. Each co-
variate was evaluated in a base model that included 
baseline severity (dichotomized as mild or moderate-to-
severe based on MMSE score), duration of symptoms, 
and pre-progression rate categories (slow, intermediate, 
fast). For the baseline covariate, the moderate and severe 
groups were combined (MMSE <20) since there were 
relatively few patients classiﬁ   ed as severe at baseline. 
Table 1. Relationship between pre-progression category and subsequent rate of decline on cognitive and functional 
measures
  Progression measures
 ADAS-Cog  VSAT  Time  VSAT  Errors  CDR-SB  IADL  PSMS
  (n = 552)  (n = 589)  (n = 589)  (n = 596)  (n = 573)  (n = 575)
Independent Variables ¶  Beta  P  Beta  P  Beta  P  Beta  P  Beta  P  Beta  P
Duration of Symptoms  1.352  <.001  7.405  <.001  -0.778  <.001  0.446  <.001  0.523   <.001  0.243  .015
Baseline Severity (mild vs. moderate/ severe)  -10.052  <001  -61.158  <001  -7.886  <.001  -3.088  <.001  -3.204  <.001  -2.129  <.001
Years  of  Follow-up  3.323 <.001  20.335  <.001 3.033 <.001 2.084 <.001 3.309  <.001 2.430 <.001
Years  of  Follow-up  Squared  0.514  .036  – NS – NS –  NS  -0.207  .003  – NS
Pre-progression Rate
 Intermediate  vs.  Fast  -4.032 .006  -20.351  .033 -3.046 .007 -1.399 .003 -1.915  .012 -0.442 .424
  Slow  vs.  Fast  -9.458 <.001  -49.417  <.001 -6.533 <.001 -2.593  <.001 -3.051 .001  -0.454  .520
               
Linear  Interaction  1*  – NS – NS – NS  0.247  .039 – NS – NS
Linear  Interaction  2*  – NS – NS – NS –  NS – NS  -1.133  <.001
Non-linear  Interaction1*  -0.807  .004  – NS – NS –  NS – NS – NS
Non-linear  Interaction  2*  -0.554  .039  – NS – NS –  NS – NS – NS
               
Model  Intercept  56.601   617.164   62.203  10.364    14.96   4.243 
* Interaction 1 = time by intermediate pre-progression group (fast = reference group); Interaction 2 = time by slow pre-progression group (fast = reference); Non-
linear Interaction 1 = time squared by intermediate pre-progression group (fast = reference group); Non-linear interaction 2 = Time squared by slow pre-progression 
group (fast = reference group).
¶ Models adjusted for age at diagnosis, sex, years of education, duration of symptoms at diagnosis, baseline severity (categorical), pre-morbid IQ, and presence of 
hallucinations and/or delusions. If the quadratic term for follow-up time and the pre-progression group by quadratic time variable were not signifi  cant, coeffi   cients for 
models with linear terms only are shown. Non-signifi  cant (NS) betas for interaction terms omitted from table.
ADAS-cog = Alzheimer’s disease Assessment Scale-cognitive subscale; VSAT = Verbal Series Attention Test; CDR-SB = Clinical Dementia Rating Scale Sum of Boxes; 
IADL = Instrumental Activities of Daily Living scale; PSMS = Physical Self-Maintenance Scale
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a ﬁ  nal model for each cognitive or functional outcome. 
Our analysis included data for up to seven years of follow-
up, since this interval represented the 90th percentile.
Cox survival analysis with robust variance estimators 
for correlated observations was used to examine the 
contribution of baseline demographic variables, 
clinician’s standardized estimate of duration, baseline 
AMNART score, and baseline MMSE score to annual 
risk of death. In the survival analysis, we considered the 
eﬀ   ect of each study variable alone and then in a full 
multivariable model. Using a conservative estimate, our 
study had 80% power to detect a reduction in hazard ratio 
of 32% (based upon N = 124 per group, medians of 8 and 
10 years, type 1 error = 5% and Bonferroni correction).
All analyses were performed using STATA version 9.0.
Results
Of 798 probable AD patients who met inclusion criteria, 
597 had the AMNART as part of their initial baseline 
assessment. Since the AMNART was a pre-speciﬁ  ed 
covariate, these 597 individuals formed the inclusion 
sample. Table 2 reports demographic characteristics and 
baseline test scores by preprogression group. From 34 to 
46% of patients had a history of or current delusions at 
their initial visit, and 13 to 22% had a history of or current 
hallucinations, but only 3 to 7% had Parkinsonian signs 
on examination. It is notable that slow progressors had a 
longer estimated duration of symptoms than inter  medi-
ate or fast progressors, consistent with slow progression. 
IQ and education were also higher in slow progressors. 
Th   e distribution of APO E epsilon 4 alleles did not diﬀ  er. 
Signiﬁ  cant  diﬀ  erences between the groups were taken 
into account in the analysis.
Table 1 contains the mixed eﬀ   ects linear regression 
coeﬃ     cients associated with pre-progression categories 
and the interaction of pre-progression categories with 
time, after adjustment for the prospectively deﬁ  ned 
covariates. Figures 1 to 6 display the ﬁ  tted regression 
lines predicted by the regression model for each outcome. 
Patients in both the slow and intermediated pre-
progression groups maintained better performance on 
the ADAS-Cog, the CDR-SB, VSAT Time and Errors and 
the IADL, compared to fast pre-progressors, but showed 
no signiﬁ   cant baseline diﬀ   erence on the PSMS. For 
example, slow progressors were about 9.5 points better 
and intermediate progressors four points better than fast 
progressors on the ADAS-Cog at baseline (Table 1). Over 
Table 2. Selected patient characteristics at baseline by preprogression category (n = 597)
  Mean ± SD or n (Percent)
Variable  Fast (N = 124)  Intermediate (n = 274)   Slow (n = 199)  P*
Age at Diagnosis (years)  74.0 ± 8.7  73.6 ± 8.8  72.9± 8.2  .516
Sex (% female)  72.6  68.3  58.3  .016
Race/Ethnic Group (% white)  90.3  91.2  90.9  .957
Years of Education  13.0± 3.1  13.7± 3.1  14.4± 3.4  <.001
Estimated duration of disease before diagnosis (yrs)  1.7± 0.9  3.4± 1.6  4.9± 2.6  <.001
Baseline MMSE  18.1± 5.0  20.3± 4.4  24.7± 3.8  <.001
First AMNART (estimated IQ)  105.5± 9.8  106.3± 10.2  110.7± 9.6  <.001
Baseline MMSE  18.1±5.0  20.3±4.4  24.7±3.8  <.001
Hallucinations (% yes at     or before Baseline)  21.0  21.9  12.6  .027
Delusions (% yes at or before Baseline)  40.32  46.0  34.2  .035
Parkinsonian Symptoms at Baseline  6.5  4.4  3.0  .147
Number of APOE ε4 Alleles (% in each group)        .573
 0  22.2  47.3  30.6
 1  19.4  46.2  34.4
 2  20.0  40.0  40.0
ADAS Cog  27.4±12.0  24.9±11.0  17.6±8.4  <.001
CDR Sum of Boxes  6.7±3.9  6.0±3.6  4.0±2.8  <.001
PSMS 7.7±2.5  7.7±2.7  7.2±2.2  .177
IADL 16.0±6.8  15.2±6.3  13.3±5.5  .002
VSAT (time)  250.2±91.6  229.15±87.6  184.6±73.7  <.001
VSAT (errors)  18.3±11.8  15.0±9.9  9.5±8.1  <.001
*P -values based on one-way analysis of variance for continuous variables or Chi square test for categorical variables
MMSE = Mini Mental Status Exam; AMNART = American version of the New Adult Reading Test; ADAS-cog = Alzheimer’s disease Assessment Scale-cognitive subscale; 
CDR = Clinical Dementia Rating Scale; PSMS = Physical Self-Maintenance Scale; IADL = Instrumental Activities of Daily Living scale; VSAT = Verbal Series Attention Test
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Page 4 of 9Figure 1. Fitted regression lines for ADAScog by pre-progression 
category calculated from model coeffi   cients shown in Table 1.
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Figure 2. Fitted regression lines for VSAT time by 
pre-progression category calculated from model coeffi   cients 
shown in Table 1.
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Figure 3. Fitted regression lines for VSAT errors by 
pre-progression category calculated from model coeffi   cients 
shown in Table 1.
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Figure 4. Fitted regression lines for CDR-SB by pre-progression 
category calculated from model coeffi   cients shown in Table 1.
2
5
2
0
o
x
e
s
1
5
R
 
S
u
m
 
o
f
 
B
o
5
1
0
C
D
0 2 4 6 8
Follow-up Years
Fast Intermediate
Slow Slow
Figure 5. Fitted regression lines for IADL by pre-progression 
category calculated from model coeffi   cients shown in Table 1.
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Figure 6. Fitted regression lines for PSMS by pre-progression 
category calculated from model coeffi   cients shown in Table 1.
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Page 5 of 9time, slow progressors gained 0.6 fewer points per year, 
and intermediate progressors gained 0.8 fewer points per 
year. Figure 1 shows that both of these groups diverged 
from the fast group over time. Similarly, slow progressors 
were 2.6 points lower and intermediate progressors 1.4 
points lower on the CDR-SB to start with (Table 1). Th  is 
relative diﬀ  erence between the slow and fast progressors 
was maintained (no signiﬁ  cant interaction term), while 
the intermediate progressors gained 0.2 points per year 
more than the fast progressors, so that they caught up 
over time (Figure 4). Th  is tendency of the intermediate 
group to speed up on the CDR-SB was probably not 
accounted for by functional deﬁ  cits, since this did not 
occur on the IADL measure (Table 1 and Figure 5). Basic 
activities of daily living assessed by PSMS were not 
diﬀ  erent at baseline and did not begin to diverge until the 
ﬁ  rst couple of years of follow up (Table 1 and Figure 6), 
but the slower rate of worsening of the slow group (1.1 
points less per year) led to more divergence from the fast 
group over time. Table 3 presents information on the 
relation  ship of the pre-speciﬁ  ed covariates to each out-
come. Not unexpectedly, age was related to cognitive 
scores, and sex to performance of complex ADLs. Pre-
morbid IQ (AMNART score) was related to the cognitive 
measures. Education did not remain a signiﬁ  cant predic-
tor of progression on any measure in the presence of the 
AMNART, consistent with our previous ﬁ  ndings  [16]. 
Th   e presence of delusions at or before baseline was asso-
ciated with worse performance on all measures except 
the VSAT, and hallucinations at or before baseline were 
related to lower scores on measures that included 
activities of daily living. We did not ﬁ  nd a relationship 
between any of our outcomes over time and the presence 
of baseline extrapyramidal signs in this population of 
probable AD subjects, from whom Dementia with Lewy 
Bodies was carefully excluded, and APO E genotype was 
not associated with the outcomes.
Average survival from ﬁ  rst visit to death was 5.5 ± 2.7 
years (median = 5.0 years). Th   e median survival times for 
each of the pre-progression categories were: 4.7 years for 
slow, 4.1 years for intermediate, and 2.5 years for rapid 
progressors adjusted for age, sex, education and baseline 
severity (Figure 7). Th   e results of Cox proportional hazards 
modeling indicated that slow progressors had signiﬁ    cantly 
reduced mortality compared to fast progressors (HR = 
0.62, 95% CI = 0.43 to 0.91, P = 0.024). Although inter-
mediate progressors are distinguishable on the survival 
curves and the curves do not cross, the diﬀ  erence between 
the intermediate and fast progressors was not statistically 
signiﬁ  cant (HR = 0.81 95% CI = 0.59 to 1.15, P = 0.24). Our 
study may have been underpowered to detect the small 
diﬀ  erence in survival between these two groups.
Discussion
We have demonstrated in a large cohort of probable 
Alzheimer’s disease patients that a simple, calculated, 
Table 3. Eff  ect of covariates: betas (P-values) for signifi  cant covariates*
 Covariates
    Sex       
Progression    (1 = male,          Extra-pyramidal  APOE
Measures  Age  0 = female)  Education  AMNART  Delusions  Hallucinations  Signs  Genotype
ADAS-Cog  -0.962 (.067)  NS  0.291 (.055)  -0.229 (<.001)  2.914 (.001)  NS  NS  NS
VSAT Time  -1.493 (<.001)  NS  NS  -2.339 (.001)  NS  NS  NS  NS
VSAT Errors  -0.179 (<.001)  NS  NS  -0.272 (<.001)  NS  NS  NS  NS
SCDR  NS NS NS NS  1.386  (<.001)  1.245  (.003)  NS  NS
IADL  NS  -2.109 (<.001)  NS  NS  2.762 (<.001)  1.619 (.008)  NS  NS
PSMS  0.037 (.055)  NS  NS  NS  1.509 (<.001)  1.945 (.009)  NS  NS
*Betas calculated in models adjusted for baseline severity, duration, pre-progression rate x time, pre-progression x time squared (if applicable), and other covariates 
that achieved the selection criterion of P <0.10. NS means the covariate did not achieve the criterion of P <.10, or did not retain this signifi  cance level when included in 
the full model.
ADAS- Cog = Alzheimer’s disease Assessment Scale-Cognitive Subscale; VSAT = Verbal Series Attention Test; CDR-SB = Clinical Dementia Rating Scale Sum of Boxes; 
IADL = Instrumental Activities of Daily Living scale; PSMS = Physical Self-Maintenance Scale; AMNART = American version of the New Adult Reading Test
Figure 7. Kaplan-Meier Survival curves by pre-progression 
group adjusted for age and sex. HR for slow vs. fast = 0.62 
(P = 0.024).
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longitudinal performance on multiple cognitive and 
func  tional measures over time. Th   ese measures of cogni-
tion (ADAScog), attention and concentration (VSAT), 
global performance (CDR-SB), and activities of daily 
living (PSMS and IADL) are highly relevant to caregiving 
needs and to patient and caregiver quality of life, as well 
as representing measures commonly employed in clinical 
trials of AD treatments. Th   e clearest and best maintained 
diﬀ  erences were observed between the slow progressors 
and those classiﬁ   ed as fast progressors, who together 
constituted 54% of the population. On the ADAScog, for 
example, slow progressors maintained nearly a 10-point 
advantage over fast progressors (intermediate progres-
sors maintained nearly a four-point advantage). Mixed 
eﬀ  ects regression modeling showed that, in eﬀ  ect, slow 
progressors are unlikely to catch up with fast progressors 
on standard outcome measures, even after up to seven 
years of observation. In fact, slow progressors diverge 
further from fast progressors over time on the ADAScog, 
while maintaining baseline diﬀ   erences on the VSAT, 
CDR-SB and IADL. Even though they did not diﬀ  er in 
performance of basic ADL (PSMS) at baseline, slow 
progressors added disability in this area at a slower rate 
than fast progressors so that their performance diverged 
over time. Slow progressors also survived longer than fast 
progressors.
Intermediate progressors (46 % of the patients) also 
maintained better cognition (ADAScog and VSAT) and 
function (IADL) compared to fast progressors, but they 
were less diﬀ  erentiated at baseline and sped up over time 
on a global measure, the CDR sum of the boxes score, 
and they were not diﬀ  erentiated at any time on the basic 
ADL (PSMS). Th   e survival diﬀ  erences between inter  me-
diate and fast progressors were not signiﬁ  cantly diﬀ  erent, 
but our study may have been underpowered to detect a 
small diﬀ  erence. Our results suggest that prognos  tica-
tions based upon initial progression rate are most reliable 
for slow and fast progressors, but that long duration 
reliability of an intermediate progression rate may depend 
upon the patient’s age and life expectancy at diagnosis. It 
would be safe to say that an intermediate progressor may 
remain so for several years, but that, if the patient lives for 
a long time after diagnosis, the rate may increase 
suﬃ   ciently to aﬀ  ect both abilities and survival.
Our methodology for classifying patients as slow, inter-
mediate or rapid progressors could be easily employed by 
clinicians to calculate pre-progression rate at an initial 
clinic visit, using the MMSE score and a standardized 
approach to estimating duration [1, 2]. Th  e clinician 
could predict that a patient would generally progress 
slowly, moderately, or rapidly over several years. How-
ever, an important question remains as to whether these 
apparently intrinsic rates of disease progression can be 
modiﬁ  ed, and this question must be resolved before the 
pre-progression approach is widely adopted for clinical 
purposes. In a separate paper, we demonstrated that 
persistent anti-dementia drug treatment impacts observed 
progression over time [20], an observation which is 
consistent with a recent analysis using a very diﬀ  erent 
approach [21]. Th  is eﬀ   ect of treatment persistence is 
signiﬁ  cant in our mixed eﬀ  ects models which also include 
the pre-progression rate, indicating that treatment may 
provide beneﬁ  t to patients regardless of their intrinsic 
progression rates. Treatment appears to alter slopes on 
measures which include the ones used in the current 
study, but we have not yet assessed whether the eﬀ  ect 
diﬀ  ers by pre-progression category.
Many investigators seek to validate biomarkers of disease 
progression, such as changes in hippocampal volume and 
serum and cerebrospinal ﬂ   uid (CSF) biomarkers. Th  e 
progression rates that are based upon clinical measures 
in such studies may need to be adjusted for early 
progression, or progression group, as well as for 
persistence of treatment, which could enhance observed 
correlations between valid biomarkers and clinical 
measures.
Our ﬁ   ndings have important implications for the 
design and interpretation of AD clinical trials. Currently, 
parallel group studies count on randomization to yield 
comparable placebo and treatment groups. Pre-
progression rates are not assessed – yet imbalances 
across the treatment groups in this important variable 
could obscure true treatment diﬀ  erences, or could create 
apparent diﬀ   erences when there is no drug eﬀ  ect, 
especially in long duration clinical trials. Further, if our 
hypothesis that the persistency of anti-dementia drug 
treatment alters progression is correct, baseline diﬀ  er-
ences in cumulative duration of drug use could create 
similar imbalances. Future clinical trials may beneﬁ  t from 
gathering systematic data regarding individual symptom 
onset in order to perform a formal estimate of duration 
[2] and to calculate pre-progression rates [1], which could 
be used to stratify patients by progression group or as a 
covariate in the analysis. For those clinical trials that 
allow background treatment with marketed anti-
dementia drugs while testing a new therapy against 
placebo, information about the quartile of persistence of 
anti-dementia treatment may also be needed to control 
for the impact of these variables in the analysis [20].
Our study has both strengths and limitations. It is a 
large study, including nearly 600 carefully diagnosed 
probable AD subjects followed for up to 15 years. Yet all 
of the subjects were followed at a single site, and we do 
not know how consistent our results would be in a multi-
site study. Although we are located at a tertiary care 
center, we are one of the few clinics providing dementia 
care in the state, and we have few barriers to access, 
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population [5]. Still we utilized a sample of convenience 
which may not be representative of the general AD 
population, and we do not know whether our results 
would be the same in a community based sample.
Further, because we did not randomize patients accord-
ing to pre-progression rates at baseline, our inclusion of 
consecutive cases yielded groups of unequal size. We 
made appropriate adjustments to our analysis for clinical 
variables shown or hypothesized to inﬂ   uence rates of 
progression and survival in AD, including age, sex, 
education, premorbid IQ, hallucinations, delusions and 
extrapyramidal features. Th  e progression group was an 
important predictor of longitudinal course even when 
these factors were taken into account.
Another strength of the study is our choice of 
standardized outcomes that are in clinical use and widely 
used in clinical trials. Th   e importance of our ﬁ  ndings is 
strengthened by the fact that the current data are 
internally consistent across multiple measures; progres-
sion groups maintained their diﬀ   erences on measures 
that included cognition, global performance, and 
activities of daily living. Th   e fact that survival data were 
available for every subject and that survival time also 
diﬀ   erentiated the slow and fast progressors provides 
additional evidence for the clinical utility of the pre-
progression rate.
Conclusions
In conclusion there is a lack of data in the medical 
literature to guide clinicians and researchers in under-
standing the progression of Alzheimer’s disease. Our data 
provide powerful evidence that prediction is possible, 
which addresses an important clinical need. Additionally, 
inclusion of the pre-progression rate in clinical trials for 
proposed AD therapies should enhance the power of 
such studies to ﬁ  nd real treatment diﬀ  erences, and could 
reduce the duration of trials designed to assess disease-
modifying therapies, which would also aid patients and 
those who care for them.
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